H.C. Wainwright Downgrades Acelyrin Inc (SLRN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Acelyrin Inc (SLRN) PT Lowered to $6 at Citi
August 14, 2024 9:25 AM EDTCiti analyst Samantha Semenkow lowered the price target on Acelyrin Inc (NASDAQ: SLRN) to $6.00 (from $8.00) while maintaining a Neutral rating.
The analyst comments "Acelyrin announced a strategic reprioritization to focus resources on development of lonigutamab (anti-IGFR1) in thyroid eye disease. The company will... More



